TABLE 2.
Associations between variables related to different medical disorders in the study population.
| Macrophages | Lymphocytes | Neutrophils | Eosinophils | Mast Cells | MEA group | |
|---|---|---|---|---|---|---|
| Premature complexes | ns | ns | ns | ns | P = .03 | P = .02 |
| Serum CK |
P = .01 r = .17 |
P < .0001 r = −.31 |
P < .0001 r = .35 |
ns | ns | P = .0004 |
|
Clinical myopathies |
ns | ns | P = .0001 | ns | ns | ns |
| DUAO group | ns | ns | ns | ns | ns | ns |
| EIPH grade |
P = .03 r = −.15 |
ns | ns | ns |
P = .04 r = .14 |
ns |
| THS | ns |
P = .0004 r = −.20 |
P = .03 r = .15 |
P = .001 r = .18 |
P < .0001 r = .24 |
ns |
| PLH | ns | ns | ns | ns | ns | ns |
| TM | ns | ns | ns | ns | ns | ns |
| TB | ns | ns | ns | ns | ns | ns |
| Macrophages | – |
P < .0001 r = −.65 |
P = .01 r = .17 |
P < .0001 r = −.26 |
P = .01 r = −.18 |
P = .03 |
| Lymphocytes |
P < .0001 r = −.65 |
– |
P < .0001 r = −.72 |
ns | ns | P < .0001 |
| Neutrophils |
P = .01 r = .17 |
P < .0001 r = −.72 |
– | ns |
P = .001 r = −.22 |
P < .0001 |
| Eosinophils |
P < .0001 r = −.26 |
ns | ns | – | ns | P = .01 |
| Mast cells |
P = .01 r = −.18 |
ns |
P = .001 r = −.22 |
ns | – | P < .0001 |
| MEA group | P = .03 | P < .0001 | P < .0001 | P = .01 | P < .0001 | – |
| ESGD grade | ns | ns | ns | ns | ns | ns |
| EGGD | ns | ns | ns | ns | ns | ns |
| THS | EIPH grade | PLH | TM | TB | DUAO group | |
|---|---|---|---|---|---|---|
| Premature complexes | ns | ns | ns | ns | ns | ns |
| Serum CK | ns | ns | ns |
P = .03 r = .14 |
ns | P = .02 |
|
Clinical myopathies |
ns | ns | ns | ns | ns | ns |
| DUAO group | P = .02 | ns | Ns | ns | ns | – |
| EIPH grade |
P < .0001 r = .32 |
– |
P = .04 r = −.13 |
ns | ns | ns |
| THS | – |
P < .0001 r = .32 |
ns | ns | ns | P = .02 |
| PLH | ns |
P = .04 r = −.13 |
– | ns |
P = .04 r = .13 |
ns |
| TM | ns | ns | ns | – |
P < .0001 r = .22 |
ns |
| TB | ns | ns |
P = .04 r = .13 |
P < .0001 r = .22 |
– | ns |
| Macrophages | ns |
P = .03 r = −.15 |
ns | ns | ns | ns |
| Lymphocytes |
P = .0004 r = −.20 |
ns | ns | ns | ns | ns |
| Neutrophils |
P = .03 r = .15 |
ns | ns | ns | ns | ns |
| Eosinophils |
P = .001 r = .18 |
ns | ns | ns | ns | ns |
| Mast cells |
P < .0001 r = .24 |
P = .04 r = .14 |
ns | ns | ns | ns |
| MEA group | ns | ns | ns | ns | ns | ns |
| ESGD grade | ns | ns | ns |
P = .01 r = .19 |
P = .02 r = .18 |
ns |
| EGGD | ns | ns | ns | ns | ns | ns |
| Premature complexes | Serum CK | Clinical myopathies | ESGD grade | EGGD | |
|---|---|---|---|---|---|
| Premature complexes | – | P = .01 | ns | ns | ns |
| Serum CK | P = .01 | – | P < .0001 |
P = .001 r = .20 |
ns |
|
Clinical myopathies |
ns | P < .0001 | – | ns | ns |
| DUAO group | ns | P = .02 | ns | ns | ns |
| EIPH grade | ns | ns | ns | ns | ns |
| THS | ns | ns | ns | ns | ns |
| PLH | ns | ns | ns | ns | ns |
| TM | ns |
P = .03 r = .14 |
ns |
P = .01 r = .19 |
ns |
| TB | ns | ns | ns |
P = .02 r = .18 |
ns |
| Macrophages | ns |
P = .01 r = .17 |
ns | ns | ns |
| Lymphocytes | ns |
P < .0001 r = −.31 |
ns | ns | ns |
| Neutrophils | ns |
P < .0001 r = .35 |
P = .0001 | ns | ns |
| Eosinophils | ns | ns | ns | ns | ns |
| Mast cells | P = .03 | ns | ns | ns | ns |
| MEA group | P = .02 | P = .0004 | ns | ns | ns |
| ESGD grade | ns |
P = .001 r = .20 |
ns | – | P = .01 |
| EGGD | ns | ns | ns | P = .01 | – |
Abbreviations: CK, creatine kinase; DUAO, dynamic upper airway obstruction; EGGD, equine glandular gastric disease; EIPH, exercise‐induced pulmonary hemorrhage; ESGD, equine squamous gastric disease; MEA, mild‐moderate equine asthma; ns, nonsignificant; PLH, pharyngeal lymphoid hyperplasia; TB, tracheal blunting; THS, total hemosiderin score; TM, tracheal mucus.